The inflammatory response seems to be significantly disrupted when AD and T2D coexist, and metabolic disease cooperates to enhance the profiles of cytokines involved in neuronal injury, amyloid and tau pathologies, or blood-brain barrier damage (Sankar et al., 2020). Here, MAPT is linked to metabolic disease.